DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Germany
  • /
  • Healthcare
Author Program NEWCreate Narrative
SHL logo

Siemens Healthineers AG Stock Price

XTRA:SHL Community·€43.7b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 76 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

SHL Share Price Performance

€38.99
-8.82 (-18.45%)
​
€45.65
Fair Value
€38.99
-8.82 (-18.45%)
14.6% undervalued intrinsic discount
€45.65
Fair Value
Price €38.99
AnalystConsensusTarget €45.65
AnalystHighTarget €56.35
AnalystLowTarget €36.00
Thu, 23 Jul 26
Fair Value€45.65
Share Pricen/a

SHL Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value €45.65 14.6% undervalued intrinsic discount

AI Diagnostics Partnerships And Healthcare Demand Will Support Global Expansion Ahead

2users have liked this narrative
0users have commented on this narrative
38users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value €56.35 30.8% undervalued intrinsic discount

Undervalued Healthcare Leader Will Benefit From Rising Noncommunicable Disease Demand Long Term

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value €36 8.3% overvalued intrinsic discount

Future Tariff Headwinds And AI Adoption Will Shape Long Term Healthcare Technology Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
SHL logo
Siemens Healthineers
14.6% undervalued intrinsic discount

AI Diagnostics Partnerships And Healthcare Demand Will Support Global Expansion Ahead

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 23 Jul
Read Narrative
SHL logo
Siemens Healthineers
30.8% undervalued intrinsic discount

Undervalued Healthcare Leader Will Benefit From Rising Noncommunicable Disease Demand Long Term

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 6 Aug
Read Narrative
SHL logo
Siemens Healthineers
8.3% overvalued intrinsic discount

Future Tariff Headwinds And AI Adoption Will Shape Long Term Healthcare Technology Margins

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 20 Aug
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystLowTarget
SHL logo

SHL: Future Returns Will Hinge On Diagnostics Margin Pressure Risk

Fair Value: €36 8.3% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
SHL logo

SHL: Future Margin Delivery Looks Set To Support Upper P E Range

Fair Value: €56.35 30.8% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
SHL logo

SHL: Margin Execution And Cyber Resilience Will Support Future Multiple Expansion

Fair Value: €45.65 14.6% undervalued intrinsic discount
38 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Excellent balance sheet and good value.

1 Risk
3 Rewards
View Full Analysis

Siemens Healthineers AG Key Details

€23.2b

Revenue

€14.1b

Cost of Revenue

€9.0b

Gross Profit

€6.8b

Other Expenses

€2.2b

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Nov 05, 2026
1.99
39.02%
9.55%
75.7%
View Full Analysis

About SHL

Founded
1896
Employees
74300
CEO
Bernhard Montag
WebsiteView website
www.siemens-healthineers.com

Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers in Germany, the United States, rest of Europe, CIS, Africa, the Middle East, the Americas, the Asia Pacific, Japan, and China. It operates in four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment offers magnetic resonance imaging, computed tomography, X-ray, molecular imaging, and ultrasound systems; and software solutions to support the reading and structured reporting of diagnostic images from different modalities. Its Diagnostics segment provides in-vitro diagnostic products and services to healthcare providers in the fields of general and specialty laboratory, and point-of-care diagnostics; and workflow solutions for laboratories and informatics products. The Varian segment offers microwave, cryoablation, and embolization technologies, as well as clinical professional services for cancer care that support oncology departments in hospitals and clinics; and customized support for cancer care operations. Its Advanced Therapies segment provides products that are designed to support image-guided minimally invasive clinical procedures in various areas, such as cardiology, neurology, and oncology; angiography systems and mobile C-arms; and AI-powered clinical applications. It also offers essential technical customer service, such as maintenance and repair; spare parts; medical equipment performance management; training; clinical education and e-learning; planning and design; financing; asset management; and managed departmental services for laboratories and healthcare facilities, as well as healthcare consulting, products, and services. It has strategic partnership with IFS to increase product lifecycle with industrial AI. The company was founded in 1896 and is headquartered in Forchheim, Germany. Siemens Healthineers AG is a subsidiary of Siemens Aktiengesellschaft.

Recent SHL News & Updates

User avatar
Narrative Update • Aug 20

SHL: Future Returns Will Hinge On Diagnostics Margin Pressure Risk

Analysts now set a slightly lower central price target for Siemens Healthineers at €36 from €37, reflecting updated expectations for profit margins and valuation multiples following recent mixed revisions to Street targets that range from €37 to €57.40. Analyst Commentary Recent Street research on Siemens Healthineers points to a mixed but generally cautious backdrop.

Recent updates

No updates

Siemens Healthineers AG Competitors

FRE logo

Fresenius SE KGaA

Symbol: XTRA:FRE
Market cap: €25.7b
FME logo

Fresenius Medical Care

Symbol: XTRA:FME
Market cap: €10.5b
OBCK logo

Ottobock SE KGaA

Symbol: XTRA:OBCK
Market cap: €3.5b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide